<div id="readability-page-1"><p>Pharming Group NV (OTCMKTS:PHGUF - Get Free Report)'s share price gapped down before the market opened on Friday . The stock had previously closed at $1.70, but opened at $1.51. Pharming Group shares last traded at $1.51, with a volume of 1,000 shares changing hands.</p><div><p><span></span><span>Get <strong>Pharming Group</strong> alerts:</span></p></div><h2>Pharming Group Stock Performance</h2><p>The business's 50 day simple moving average is $1.78 and its two-hundred day simple moving average is $1.60. The firm has a market capitalization of $1.01 billion, a PE ratio of 151.15 and a beta of 0.42. The company has a current ratio of 3.16, a quick ratio of 2.39 and a debt-to-equity ratio of 0.46. </p><h2>About Pharming Group</h2> (Get Free Report)<p>Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.  </p><p>Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.</p><h2>Read More</h2><ul><li>Five stocks we like better than Pharming Group</li><li>BNZI stands out as a Zacks Buy. Earnings momentum and analyst upgrades align</li><li>Your name isn't on our protected list yet</li><li>Silver paying 20% dividend. Plus 68% share gains</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li><li>What a Former CIA Agent Knows About the Coming Collapse</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Pharming Group Right Now?</h2><p>Before you consider Pharming Group, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.</p><p>While Pharming Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Pharming Group (OTCMKTS:PHGUF) shares gapped down from $1.70 to $1.51 before market opening on Friday, with a trading volume of 1,000 shares. The company, a Netherlands-based biopharmaceutical firm, specializes in protein replacement therapies for rare diseases, notably RUCONEST for hereditary angioedema. Pharming has a market cap of $1.01 billion, a PE ratio of 151.15, and a current ratio of 3.16. Analysts currently rate the stock as a Hold, but suggest other stocks may be better investment options.</p>

Market Beat

SPDR S&P Health

iShares US Pharma

VanEck Biotech ETF

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

Scpharmaceuticals

SPDR S&P Biotech

VG Health

Ark Genomic Revolution ETF

Direxion S&P Biotech Bear 3X

Charming Medical

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Pharming Group NV

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

Pharming Group (OTCMKTS:PHGUF) Shares Gap Down   - Here's What Happened